Nabi – Nanomédecine, Biologie Extracellulaire, Intégratome et Innovations en Santé

NABI Laboratory: Mission and Objectives

The NABI Laboratory (Nanomedicine, Extracellular Biology, Integratome, and Health Innovations), established on January 1, 2025, by Université Paris Cité, CNRS, and INSERM, aims to develop next-generation therapeutic approaches and make them accessible to the greatest number of patients.

Through interdisciplinary research and our technology accelerator, the IVETh Bioproduction and Biotherapy Integrator, our ambition is to democratize biotherapies and de-risk their bioproduction.

Live/dead assay of fibroblasts on beads (from Léa Jabbour)

Schematic of an antero-cutaneous fistula (by Anna Sebbagh)

Co-culture of cholangiocarcinoma cells (GFP) and fibroblasts (mCherry) exposed to iron oxide nanoflowers decorated with gold NPs (by Sonia Becharef)

Schematic of an intestine affected by Crohn disease (by Anna Sebbagh)

Schematic of mesenchymal stem cells (by Anna Sebbagh)

Locomotion pattern of C. elegans (BPJ cover, JM Di Meglio)

Schematic of a mixed lymphocyte reaction assay (by Anna Sebbagh)

 

Schematic of an extracellular vesicle (by Anna Sebbagh)

Schematic of Atomic Force Microscopy (AFM) on polymers (by JM Di Meglio)

TEM on fibroblast exposed to Gold salts (by Giulio Avveduto).

Our Objectives

Understanding the role and fate of exogenous and endogenous nanoparticles in the body

  • Investigate their properties, transformations, and impact within the organism.
  • Decipher intercellular communication mechanisms involving biological nanoparticles (extracellular vesicles, viral particles, mitochondria, etc.).

Developing innovative (bio)therapies

  • Leverage biological nanoparticles as therapeutic vectors in nanomedicine or as alternatives to cell therapies.
  • Optimize immunotherapies and other precision treatments through external physical control.
  • Overcome treatment resistance mechanisms with innovative delivery strategies.

Integrating bioproduction challenges

  • Develop robust, controlled, and eco-friendly processes for the production of biological nanoparticles for therapeutic use.
  • Ensure the reproducibility, safety, and scalability of manufacturing processes through AI-driven optimization for industrial and clinical transfer.
  • Develop quality control methods at the nanometric scale.

Facilitating the transfer of innovations to clinical applications

  • Transform scientific breakthroughs into concrete medical applications.
  • Bridge the gap between fundamental research and clinical trials to directly benefit patients.

Promoting an interdisciplinary and collaborative approach

  • Bring together researchers in engineering, physics, biology, medicine, chemistry, and AI for an integrated approach.
  • Develop partnerships with academic institutions and industry to accelerate innovation.

Addressing global and planetary health challenges

  • Contribute to disease prevention and treatment by developing safer, more effective, and more targeted therapies.
  • Integrate environmental and ethical considerations into the development of nanomedicines and bioprocesses.

The NABI Laboratory is committed to pushing the boundaries of nanomedicine to make biotherapies accessible to all and to secure their large-scale production.

News

Vincent Fleury invité à la “Science CQFD” sur France culture

Depuis quelques années, des équipes de biologistes prétendent se rapprocher de la fabrication d’embryons synthétiques, à partir de cellules souches. Ces travaux posent des questions scientifiques, juridiques et éthiques. Vincent Fleury en débattra le 23 novembre vers 16h sur France culture.

Seminar – “Peptidic Bioactivable AuNCs for Biosensing and Extracellular Vesicles or Cellular Labeling” and “Extracellular Vesicles in seminal fluids, their morphological analysis, and size in healthy patients and others with two pathologies.”

Seminar by Valérie Marchi and Célia Ravel, 7th November 2023, 12pm, Salle des Thèses 3rd Floor. Topic: "Peptidic Bioactivable AuNCs for Biosensing and Extracellular Vesicles or Cellular Labeling" and "Extracellular Vesicles in seminal fluids, their morphological...

Lancement du projet CARN

Le 30 août 2023 a eu lieu la journée de lancement du projet CARN. Le projet CARN, coordonné par le laboratoire MSC vise à développer des  biothérapies innovantes basées sur la délivrance locale d’ARN thérapeutiques par des vésicules hybrides fonctionnalisées pour la régénération musculo-squelettique. Le projet CARN  a été selectionné par le PEPR 2030

Plusieurs mécanismes de neutralisation des nanoparticules découverts dans les cellules pulmonaires

Comment l’organisme réagit-il en cas d’inhalation de nanoparticules ? Les chercheu.r.se.s de MscMed et leurs collègues ont étudié l’évolution de nanofeuillets de disulfure de molybdène dans des poumons de souris jusqu’à un mois après leur inhalation. Publiés dans la revue Advanced Materials, ces travaux montrent que les macrophages pulmonaires peuvent transformer ces nanoparticules et les enrouler afin de réduire leur surface de contact, et donc leur toxicité, et seraient également capables de moduler la réaction inflammatoire induite.

Journal club – Extracellular vesicles – matrix interactions

Seminar by Lucile Alexandre, 17th October 2023, 1pm, Salle des Thèses 3rd Floor. Topic: Extracellular vesicle–matrix interactions, Koushik Debnath, Kevin Las Heras, Ambar Rivera, Stephen Lenzini & Jae-Won Shin, Nature reviews materials, March 2023...

Financial supports